Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Aoxing Pharmaceutical Company, a developer of narcotic and pain-management products, has announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has received a new production license for ligustrazine phosphate injection from the China State Food and Drug Administration for treatment of ischemic cerebrovascular disease, or ischemic stroke.
Subscribe to our email newsletter
Ligustrazine phosphate injection is used intravenously in hospital for treating ischemic cerebrovascular disease, such as insufficiency of blood-supply, cerebral thrombosis as well as cerebral embolism.
Juan Han, chairman and CEO of China Aoxing, said: “Stroke is a silent killer ranked the third leading cause of death in the adult population. Ligustrazine phosphate is an effective intravenous injection drug in hospitals to treat this public heath problem.
“We are very excited to have another injection drug approved for our patients in hospital. This approval further underscores China Aoxing’s long-term commitment to developing high quality hospital care therapies. We are looking forward to launching this product in early 2009.”